OS Therapies Acquires Advaxis Immunotherapies Assets from Ayala
April 9, 2025
Company now listeria-based cancer immunotherapy world leader OS Therapies , a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has